Rafael Holdings, Inc. (RFL) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on December 2, 2025. The report details a corporate action related to the merger with Cyclo Therapeutics, Inc. ("Cyclo").
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the issuance and terms of new warrants.
Material Changes and Corporate Actions
- Warrant Issuance: The Company issued 1,078,796 new warrants (the "Warrants") in exchange for warrants previously held by Cyclo Therapeutics, Inc. (the "Cyclo Warrants").
- Underlying Shares: The Warrants are exercisable for an aggregate of 380,253 shares of the Company's Class B common stock.
- Exercise Price: The exercise price is set at $14.19 per share.
- Exchange Ratio: Each Warrant is exercisable for approximately 0.3525 of a share of Class B common stock, reflecting the exchange ratio used in the Merger.
- Listing: The Warrants are listed on the NYSE American under the symbol "RFL-WT".
- Expiration: The Warrants expire at 5:00 pm EST on December 11, 2025, and are exercisable at any time until that date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are disclosed beyond the standard terms of the warrant issuance and expiration.
Key Facts for Investor Verification
- Verify the trading status and volume of the new warrant symbol "RFL-WT" on the NYSE American.
- Confirm the exact expiration date of December 11, 2025, to assess the remaining time value of the warrants.
- Review the full Merger agreement to understand the context of the 0.3525 exchange ratio and the $14.19 exercise price.
- Check the Company's latest 10-K or 10-Q for the most recent financial position, as this 8-K does not contain financial statements.